21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.


Department of Surgery, University of Minnesota, United States. Electronic address: [Email]


The 21-gene recurrence score (RS) (Oncotype Dx, Genomic Health, Redwood City Ca) has not been validated in an older cohort with estrogen receptor (ER)-positive breast cancer. The objective of this study was to evaluate RS validity in a group of older women with ER-positive breast cancer.


Breast Cancer,Genomic Testing,Geriatric,Recurrence Score,